Hevener Kirk E, Santarsiero Bernard D, Lee Hyun, Jones Jesse A, Boci Teuta, Johnson Michael E, Mehboob Shahila
Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Avenue, Suite 571, Memphis, TN 38163-2198, USA.
Center for Pharmaceutical Biotechnology, University of Illinois at Chicago, 900 South Ashland Avenue, Suite 3100, Chicago, IL 60607-7173, USA.
Acta Crystallogr F Struct Biol Commun. 2018 Feb 1;74(Pt 2):105-112. doi: 10.1107/S2053230X18000262. Epub 2018 Jan 26.
Enoyl-acyl carrier protein (ACP) reductase II (FabK) is a critical rate-limiting enzyme in the bacterial type II fatty-acid synthesis (FAS II) pathway. FAS II pathway enzymes are markedly disparate from their mammalian analogs in the FAS I pathway in both structure and mechanism. Enzymes involved in bacterial fatty-acid synthesis represent viable drug targets for Gram-negative pathogens, and historical precedent exists for targeting them in the treatment of diseases of the oral cavity. The Gram-negative organism Porphyromonas gingivalis represents a key causative agent of the costly and highly prevalent disease known as chronic periodontitis, and exclusively expresses FabK as its enoyl reductase enzyme in the FAS-II pathway. Together, these characteristics distinguish P. gingivalis FabK (PgFabK) as an attractive and novel narrow-spectrum antibacterial target candidate. PgFabK is a flavoenzyme that is dependent on FMN and NADPH as cofactors for the enzymatic reaction, which reduces the enoyl substrate via a ping-pong mechanism. Here, the structure of the PgFabK enzyme as determined using X-ray crystallography is reported to 1.9 Å resolution with endogenous FMN fully resolved and the NADPH cofactor partially resolved. PgFabK possesses a TIM-barrel motif, and all flexible loops are visible. The determined structure has allowed insight into the structural basis for the NADPH dependence observed in PgFabK and the role of a monovalent cation that has been observed in previous studies to be stringently required for FabK activity. The PgFabK structure and the insights gleaned from its analysis will facilitate structure-based drug-discovery efforts towards the prevention and treatment of P. gingivalis infection.
烯酰-酰基载体蛋白(ACP)还原酶II(FabK)是细菌II型脂肪酸合成(FAS II)途径中的关键限速酶。FAS II途径的酶在结构和机制上与FAS I途径中的哺乳动物类似物明显不同。参与细菌脂肪酸合成的酶是革兰氏阴性病原体可行的药物靶点,并且在口腔疾病治疗中针对它们存在历史先例。革兰氏阴性菌牙龈卟啉单胞菌是一种被称为慢性牙周炎的代价高昂且高度流行疾病的关键病原体,并且在FAS-II途径中仅表达FabK作为其烯酰还原酶。这些特征共同使牙龈卟啉单胞菌FabK(PgFabK)成为有吸引力的新型窄谱抗菌靶点候选物。PgFabK是一种黄素酶,依赖FMN和NADPH作为酶促反应的辅因子,通过乒乓机制还原烯酰底物。在此,报道了使用X射线晶体学确定的PgFabK酶的结构,分辨率为1.9 Å,内源性FMN完全解析,NADPH辅因子部分解析。PgFabK具有TIM桶基序,所有柔性环都可见。所确定的结构有助于深入了解PgFabK中观察到的对NADPH依赖性的结构基础以及先前研究中观察到的对FabK活性严格要求的单价阳离子的作用。PgFabK结构及其分析所得的见解将有助于基于结构的药物发现工作,以预防和治疗牙龈卟啉单胞菌感染。